secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001411685-25-000062
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026
--------------------------------------------------------------------------------

- Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.
- Cash, cash equivalents, and marketable securities at $63.2M as of June 30, 2025.
- Topline data from PALISADE-3 Phase 3 trial of fasedienol (SAD) expected Q4 2025; PALISADE-4 data H1 2026.
- PH80 for menopausal hot flashes – IND preparation underway for further Phase 2 development.
- Appointed Elissa Cote as Chief Corporate Development Officer in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/0001411685-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/vtgn-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer